Breaking news headlines, stories and live updates on current affairs from across the globe. Complete coverage on the latest ...
Pfizer and Valneva said Monday their Lyme disease vaccine showed more than 70% efficacy in a late-stage study, even as it missed its main goal. Subscribe to read this story ad-free Get unlimited ...
Pfizer said it will seek regulatory approval for a Lyme disease vaccine candidate despite failing a late-stage trial. Pfizer said not enough people contracted Lyme disease to be confident in the ...
Four doses of an experimental vaccine to protect against Lyme disease reduced the number of tick-borne infections by more than 70 percent, according to Pfizer and Valneva, the pharmaceutical companies ...
Pharmaceutical giant Pfizer and French vaccine maker Valneva reported positive topline results from their phase three study ...
LONDON, April 1 (Reuters) - Vaccine makers Pfizer (PFE.N), opens new tab and BioNTech (22UAy.DE), opens new tab halted a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to ...
Results from a phase 3 clinical trial of Pfizer’s Lyme disease vaccine candidate found it was more than 70 percent effective at preventing the illness. Participants in Pfizer’s trial received four ...
Pfizer Inc. said its experimental Lyme disease vaccine was 73% effective against the tick-borne illness, though fewer-than-expected cases in a study made it hard to determine how well it works on a ...
An experimental Lyme disease vaccine from Pfizer PFE-1.10%decrease; red down pointing triangle and Valneva VLA 1.71%increase; green up pointing triangle didn’t conclusively succeed in a large study, ...
This week, Pfizer and French vaccine company, Valneva, released phase 3 clinical trial data for PF-0730740, a four-dose Lyme disease vaccine they developed together that is about 70% effective. While ...
Add Yahoo as a preferred source to see more of our stories on Google. Pfizer Inc. signage is seen on July 22, 2020 in New York City. (Jeenah Moon via Getty Images) This story was originally published ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results